Rivaroxaban found noninferior to enoxaparin in acutely ill

Rivaroxaban found noninferior to enoxaparin in acutely ill
In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

Alexander T. Cohen, M.D., from King's College Hospital in London, and colleagues randomly assigned 8,101 patients (40 years of age and older) with reduced mobility and an acute requiring hospitalization to receive subcutaneous (40 mg once daily) for 10 days and oral placebo for 35 days, or subcutaneous placebo for 10 days and oral rivaroxaban (10 mg once daily) for 35 days.

At day 10, the researchers found that 2.7 percent of the rivaroxaban group and 2.7 percent of the enoxaparin group experienced asymptomatic proximal or symptomatic venous (relative risk, 0.97; P = 0.003 for non-inferiority). At day 35, 4.4 percent of the rivaroxaban group and 5.7 percent of the enoxaparin group experienced this outcome (relative risk, 0.77; P = 0.02). Major or clinically relevant non-major bleeding occurred in a significantly greater percentage of the rivaroxaban group both at day 10 (2.8 versus 1.2 percent) and at day 35 (4.1 versus 1.7 percent).

"The efficacy of standard-duration rivaroxaban was similar to that of enoxaparin, whereas the efficacy of extended-duration rivaroxaban was superior to that of enoxaparin," Cohen and colleagues conclude. "However, rivaroxaban was associated with an increased risk of clinically relevant bleeding."

The study was funded by Bayer, manufacturer of rivaroxaban, and Janssen, marketer of rivaroxaban; several authors disclosed to pharmaceutical companies, including Bayer and Janssen.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Stroke risk high when anti-clotting drugs stopped

Apr 25, 2012

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Recommended for you

Senegal monitors contacts of 1st Ebola patient

1 hour ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

7 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

13 hours ago

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments